JOURNEY MEDICAL CORP (DERM) Fundamental Analysis & Valuation

NASDAQ:DERM • US48115J1097

Current stock price

5.1 USD
-0.23 (-4.32%)
Last:

This DERM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. DERM Profitability Analysis

1.1 Basic Checks

  • In the past year DERM has reported negative net income.
  • In the past year DERM has reported a negative cash flow from operations.
  • DERM had negative earnings in each of the past 5 years.
  • In the past 5 years DERM reported 4 times negative operating cash flow.
DERM Yearly Net Income VS EBIT VS OCF VS FCFDERM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of DERM (-12.08%) is better than 64.58% of its industry peers.
  • DERM's Return On Equity of -35.89% is fine compared to the rest of the industry. DERM outperforms 60.42% of its industry peers.
Industry RankSector Rank
ROA -12.08%
ROE -35.89%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DERM Yearly ROA, ROE, ROICDERM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K 2K

1.3 Margins

  • The Gross Margin of DERM (66.17%) is better than 72.92% of its industry peers.
  • DERM's Gross Margin has been stable in the last couple of years.
  • DERM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.36%
GM growth 5Y-0.32%
DERM Yearly Profit, Operating, Gross MarginsDERM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. DERM Health Analysis

2.1 Basic Checks

  • DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for DERM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DERM Yearly Shares OutstandingDERM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DERM Yearly Total Debt VS Total AssetsDERM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • DERM has an Altman-Z score of 0.67. This is a bad value and indicates that DERM is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.67, DERM is in line with its industry, outperforming 53.13% of the companies in the same industry.
  • DERM has a Debt/Equity ratio of 0.79. This is a neutral value indicating DERM is somewhat dependend on debt financing.
  • DERM has a worse Debt to Equity ratio (0.79) than 69.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC10.4%
DERM Yearly LT Debt VS Equity VS FCFDERM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • A Current Ratio of 1.79 indicates that DERM should not have too much problems paying its short term obligations.
  • DERM's Current ratio of 1.79 is on the low side compared to the rest of the industry. DERM is outperformed by 67.19% of its industry peers.
  • A Quick Ratio of 1.53 indicates that DERM should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.53, DERM is not doing good in the industry: 64.06% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.53
DERM Yearly Current Assets VS Current LiabilitesDERM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. DERM Growth Analysis

3.1 Past

  • DERM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.33%, which is quite impressive.
  • Looking at the last year, DERM shows a quite strong growth in Revenue. The Revenue has grown by 10.20% in the last year.
  • The Revenue has been growing slightly by 6.79% on average over the past years.
EPS 1Y (TTM)53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.33%
Revenue 1Y (TTM)10.2%
Revenue growth 3Y-5.66%
Revenue growth 5Y6.79%
Sales Q2Q%18.05%

3.2 Future

  • The Earnings Per Share is expected to grow by 117.53% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 45.74% on average over the next years. This is a very strong growth
EPS Next Y154.11%
EPS Next 2Y117.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year38.29%
Revenue Next 2Y46.84%
Revenue Next 3Y45.74%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DERM Yearly Revenue VS EstimatesDERM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
DERM Yearly EPS VS EstimatesDERM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. DERM Valuation Analysis

4.1 Price/Earnings Ratio

  • DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 19.80, the valuation of DERM can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, DERM is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
  • DERM's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.69.
Industry RankSector Rank
PE N/A
Fwd PE 19.8
DERM Price Earnings VS Forward Price EarningsDERM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DERM Per share dataDERM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

  • DERM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as DERM's earnings are expected to grow with 117.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y117.53%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DERM Dividend Analysis

5.1 Amount

  • DERM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DERM Fundamentals: All Metrics, Ratios and Statistics

JOURNEY MEDICAL CORP

NASDAQ:DERM (4/9/2026, 10:12:10 AM)

5.1

-0.23 (-4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25
Earnings (Next)N/A
Inst Owners39.39%
Inst Owner Change0%
Ins Owners12.01%
Ins Owner Change0%
Market Cap139.03M
Revenue(TTM)61.86M
Net Income(TTM)-11.43M
Analysts82
Price Target13.77 (170%)
Short Float %13.04%
Short Ratio13.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.09%
Min EPS beat(2)-85.76%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)-21.97%
Min EPS beat(4)-85.76%
Max EPS beat(4)25.7%
EPS beat(8)3
Avg EPS beat(8)-22.5%
EPS beat(12)5
Avg EPS beat(12)30.22%
EPS beat(16)6
Avg EPS beat(16)19.13%
Revenue beat(2)0
Avg Revenue beat(2)-12.37%
Min Revenue beat(2)-16.43%
Max Revenue beat(2)-8.32%
Revenue beat(4)1
Avg Revenue beat(4)-4.84%
Min Revenue beat(4)-16.43%
Max Revenue beat(4)6.86%
Revenue beat(8)2
Avg Revenue beat(8)-3.77%
Revenue beat(12)4
Avg Revenue beat(12)4.79%
Revenue beat(16)5
Avg Revenue beat(16)1.79%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-188.9%
EPS NQ rev (3m)-188.9%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-21.11%
Revenue NQ rev (3m)-21.11%
Revenue NY rev (1m)-11.26%
Revenue NY rev (3m)-11.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.8
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 4.36
P/tB 32.74
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)0.26
Fwd EY5.05%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS2.27
BVpS1.17
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.08%
ROE -35.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.17%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.36%
GM growth 5Y-0.32%
F-Score4
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.53
Altman-Z 0.67
F-Score4
WACC10.4%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.33%
EPS Next Y154.11%
EPS Next 2Y117.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.2%
Revenue growth 3Y-5.66%
Revenue growth 5Y6.79%
Sales Q2Q%18.05%
Revenue Next Year38.29%
Revenue Next 2Y46.84%
Revenue Next 3Y45.74%
Revenue Next 5YN/A
EBIT growth 1Y55.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year350.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y48.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.31%
OCF growth 3YN/A
OCF growth 5YN/A

JOURNEY MEDICAL CORP / DERM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of JOURNEY MEDICAL CORP (DERM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DERM.


What is the valuation status of JOURNEY MEDICAL CORP (DERM) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOURNEY MEDICAL CORP (DERM). This can be considered as Overvalued.


How profitable is JOURNEY MEDICAL CORP (DERM) stock?

JOURNEY MEDICAL CORP (DERM) has a profitability rating of 2 / 10.


How financially healthy is JOURNEY MEDICAL CORP?

The financial health rating of JOURNEY MEDICAL CORP (DERM) is 2 / 10.


Can you provide the expected EPS growth for DERM stock?

The Earnings per Share (EPS) of JOURNEY MEDICAL CORP (DERM) is expected to grow by 154.11% in the next year.